<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paraneoplastic cerebellar degeneration</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paraneoplastic cerebellar degeneration</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Paraneoplastic cerebellar degeneration</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Josep Dalmau, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Myrna R Rosenfeld, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H15807611"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Paraneoplastic neurologic syndromes are a heterogeneous group of neurologic disorders associated with systemic cancer and caused by mechanisms other than metastases, metabolic and nutritional deficits, infections, coagulopathy, or side effects of cancer treatment.</p><p>Paraneoplastic cerebellar degeneration (PCD) is an uncommon disorder that can be associated with any cancer; the most commonly associated are lung cancer (particularly small cell lung cancer [SCLC]), gynecologic and breast cancer, and lymphoma (particularly Hodgkin disease [HD]) [<a href="#rid1">1</a>]. The neurologic symptoms frequently precede or coincide with the diagnosis of cancer.</p><p>This topic discusses PCD. An overview of paraneoplastic syndromes and other paraneoplastic disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system"</a> and  <a class="medical medical_review" href="/d/html/5190.html" rel="external">"Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle"</a> and  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H15805935"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The cerebellum is a frequent target of paraneoplastic autoimmunity. All paraneoplastic antibodies have been reported in association with PCD [<a href="#rid2">2-17</a>]. Some of these autoantibodies are associated with specific clinical settings  (<a class="graphic graphic_table graphicRef135170" href="/d/graphic/135170.html" rel="external">table 1</a>) that may help focus the search for an underlying occult malignancy.</p><p>In addition to antibody-mediated immune responses, cytotoxic T cell responses appear to be important in the pathogenesis of PCD and are most likely the primary mediators of the pathologic damage [<a href="#rid7">7,18,19</a>].</p><p>Pathologic examination shows marked degeneration of the Purkinje cells with minimal involvement of the molecular or granular cell layers along with inflammation, depending on the stage of the disease, in the cerebellar cortex, deep cerebellar nuclei, and inferior olivary nuclei  (<a class="graphic graphic_picture graphicRef60259" href="/d/graphic/60259.html" rel="external">picture 1</a>) [<a href="#rid1">1,2</a>]. In patients who have PCD coexisting with Lambert-Eaton myasthenic syndrome (LEMS), the immunologic target of the antibodies appears to be the P/Q type voltage-gated calcium channel of the cerebellar molecular layer [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/d/html/5174.html" rel="external">"Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis", section on 'Pathophysiology'</a>.)</p><p class="headingAnchor" id="H2924210475"><span class="h1">ASSOCIATED ANTIBODIES</span><span class="headingEndMark"> — </span>Only three antibodies, anti-Yo, anti-Tr (or anti-Delta/Notch-like epidermal growth factor-related receptor [DNER]), and anti-metabotropic glutamate receptor 1 (mGluR1), predominantly associate with cerebellar dysfunction; the other paraneoplastic antibodies often associate with symptoms involving other areas of the nervous system, with or without cerebellar dysfunction.</p><p class="headingAnchor" id="H1690262283"><span class="h2">Anti-Yo</span><span class="headingEndMark"> — </span>The most common among the associated antibodies, anti-Yo antibodies (also called Purkinje cell cytoplasmic antibody type 1 [PCA-1]) primarily occur in patients with PCD who have breast cancer or tumors of the ovary, endometrium, and fallopian tube [<a href="#rid4">4,5,20-22</a>]. Rare cases of anti-Yo-associated PCD have been described in men with adenocarcinoma [<a href="#rid23">23-27</a>].</p><p>The target antigens of anti-Yo antibodies are the cerebellar degeneration-related (CDR) proteins that are expressed by Purkinje cells  (<a class="graphic graphic_picture graphicRef60259" href="/d/graphic/60259.html" rel="external">picture 1</a>) and ovarian and breast cancers [<a href="#rid6">6,7,28,29</a>].</p><p class="headingAnchor" id="H4194160758"><span class="h2">Anti-Tr</span><span class="headingEndMark"> — </span>DNER antibodies [<a href="#rid30">30</a>] appear to be specific for cerebellar degeneration associated with Hodgkin disease (HD) and less commonly non-Hodgkin lymphoma [<a href="#rid8">8,9,31-34</a>]. In some patients, these antibodies are detectable in the cerebrospinal fluid (CSF) but not in serum.</p><p>In contrast to other clinical settings, PCD often develops after the diagnosis of HD or when the patient's tumor is in remission [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H3439309621"><span class="h2">Anti-mGluR1</span><span class="headingEndMark"> — </span>Antibodies to mGluR1 were initially identified in two patients with paraneoplastic cerebellar ataxia and Hodgkin lymphoma. Additional patients have since been reported, all with cerebellar ataxia and most without an associated cancer  (<a class="graphic graphic_table graphicRef135170" href="/d/graphic/135170.html" rel="external">table 1</a>) [<a href="#rid16">16,35,36</a>].</p><p class="headingAnchor" id="H3091566407"><span class="h2">Others</span><span class="headingEndMark"> — </span>The remaining antibodies have been reported in association with a variety of neurologic syndromes, both with and without accompanying cerebellar dysfunction.</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-Hu antibodies (also called antineuronal nuclear antibody, type 1 or ANNA-1) are prevalent in patients with small cell lung cancer (SCLC) and PCD. In one report of 57 such patients, 44 percent had a high titer of anti-Hu antibodies [<a href="#rid2">2</a>]. These patients are more likely to have multifocal neurologic disease and severe disability than other patient groups [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-Hu encephalomyelitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-P/Q type calcium channel antibodies were the second most commonly associated antibody (seen in 24 percent) in the above series of patients with SCLC and PCD [<a href="#rid2">2</a>]. These antibodies were present in all patients who also had Lambert-Eaton myasthenic syndrome (LEMS), as well as in some patients with cerebellar dysfunction without LEMS [<a href="#rid3">3,38,39</a>]. Antitumor treatment did not alter the course of the cerebellar degeneration, but it did improve the myasthenic symptoms. LEMS is discussed separately. (See  <a class="medical medical_review" href="/d/html/5174.html" rel="external">"Lambert-Eaton myasthenic syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-Ri (ANNA-2) antibodies have been associated with PCD, primarily in patients with breast cancer, gynecologic cancers, and SCLC [<a href="#rid37">37,40</a>]. Multifocal disease also occurs in this group, with associated encephalitis and/or opsoclonus myoclonus occurring in more than half.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-CRMP5 (or CV2) antibodies, directed against a cytoplasmic antigen in some glial cells and against peripheral nerve antigens [<a href="#rid10">10</a>], have been associated with several syndromes, including PCD, limbic encephalitis, encephalomyelitis, chorea, peripheral neuropathy, and optic neuritis [<a href="#rid10">10-12,41</a>]. The most common tumors are SCLC and thymoma. Anti-CRMP5 antibodies often associate with thymoma and SCLC [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-CRMP5 encephalomyelitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies to Ma proteins, which are selectively expressed in brain, testis, and some tumors, can occur in patients with paraneoplastic brainstem and cerebellar dysfunction associated with a variety of tumors arising in the testes (germ-cell tumors), breast, colon, and parotid gland, among others [<a href="#rid43">43,44</a>]. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Ma2-associated encephalitis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies to Kelch-like protein 11 (KLHL11) can be found in some patients with isolated or predominant cerebellar ataxia associated with testicular cancer [<a href="#rid45">45,46</a>]. These patients often have sensorineural hearing loss or vestibular symptoms. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Others'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies to Zic4 have been described in patients with neurologic disorders including cerebellar dysfunction and SCLC. These patients often have concurrent anti-Hu or CRMP5 antibodies. Patients with isolated Zic4 antibodies are more likely to develop cerebellar dysfunction than those with concurrent immunities [<a href="#rid13">13,47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies to protein kinase C, a protein highly expressed in the Purkinje cells of the cerebellum, have been described in two patients with PCD: one with non-SCLC and the other with papillary adenocarcinoma of hepatobiliary origin [<a href="#rid48">48,49</a>].</p><p></p><p>Other antibodies have been reported in isolated patients with cerebellar ataxia or cerebellar degeneration. However, the clinical information and number of cases reported are too limited in order to know whether they manifest as pure cerebellar syndromes.</p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies against the carbonic anhydrase related protein VIII (CARP VIII) have been identified in two patients with PCD, one with melanoma [<a href="#rid17">17</a>] and the other with ovarian adenocarcinoma [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-inositol 1,4,5-triphosphate receptor 1 (ITPR1) antibodies have been described in four patients but only one had cancer (breast cancer) that developed 11 years after the onset of the cerebellar syndrome [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies against tripartite motif-containing [TRIM] protein 9 or TRIM protein 67 were found in two patients with a subacute, progressive, severe cerebellar ataxia associated with adenocarcinoma of the lung [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies against the metabotropic glutamate receptor 2 (mGluR2) have been reported in two patients with paraneoplastic cerebellar ataxia. One 78-year-old patient had a progressive syndrome and a small cell tumor of unknown origin and the other was a three-year-old child with steroid-responsive acute cerebellitis preceding the diagnosis of an alveolar rhabdomyosarcoma [<a href="#rid53">53</a>].</p><p></p><p class="headingAnchor" id="H15807251"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients with PCD typically present with dizziness, nausea, and vomiting, often beginning acutely, and followed several days later by gait instability, oscillopsia, diplopia, both truncal and appendicular ataxia, dysarthria, and dysphagia [<a href="#rid20">20,21,37,54</a>]. Symptoms typically continue to worsen for weeks to months before stabilizing. Severe disability with inability to walk or even sit unsupported, inability to write or feed oneself, and limited communication secondary to dysarthria are common, with some patients having a somewhat better outcome.</p><p>In some patients, PCD occurs along with other neurologic signs. As an example, when cerebellar degeneration occurs with encephalomyelitis, the underlying tumor is small cell lung cancer (SCLC) in approximately 80 percent of cases [<a href="#rid2">2</a>]. As noted above, Lambert-Eaton myasthenic syndrome (LEMS) can occur with PCD in patients with SCLC who have anti-P/Q type calcium channel antibodies. Even patients with anti-Yo antibodies and relatively isolated PCD have detectable cognitive deficits approximately 20 percent of the time [<a href="#rid20">20,55</a>].</p><p>Most patients (60 to 70 percent) with PCD do not have a cancer diagnosis at the onset of their neurologic symptoms [<a href="#rid20">20,21,37</a>].</p><p class="headingAnchor" id="H15807258"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnostic approach to patients with PCD includes ruling out other diagnoses, confirming and characterizing the paraneoplastic syndrome, and identifying the underlying neoplasm, if this is not previously known.</p><p class="headingAnchor" id="H15807265"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of cerebellar ataxia includes cerebellar and brainstem metastases, toxic and metabolic causes, and neurodegenerative causes [<a href="#rid55">55</a>]. Alcoholism, vitamin deficiency (thiamine, vitamin E, cobalamin), hypothyroidism, cerebrovascular disease, demyelination, infectious or postinfectious cerebellitis, Miller-Fisher syndrome, antiglutamic acid decarboxylase (GAD)-associated cerebellar ataxia, Creutzfeldt-Jakob disease (CJD), human immunodeficiency virus (HIV), and celiac disease should be specifically considered. Medication lists should also be reviewed for possible contributors. (See  <a class="medical medical_review" href="/d/html/4910.html" rel="external">"Approach to abnormal gait in adults", section on 'Cerebellar ataxia'</a>.)</p><p class="headingAnchor" id="H15807406"><span class="h2">Testing</span><span class="headingEndMark"> — </span>Diagnostic evaluation typically begins with neuroimaging and laboratory testing to exclude other conditions.</p><p>Magnetic resonance imaging (MRI) is usually not helpful for positive diagnosis of PCD but is important to exclude metastatic and cerebrovascular disease. In rare instances of PCD, contrast enhancement in the cerebellar folia can be found in acute phases of the disease, and positron emission tomography (PET) may reveal hypermetabolism [<a href="#rid56">56</a>]. Diffuse cerebellar atrophy develops subsequently but is not sensitive early in the course of symptoms [<a href="#rid20">20,41,57</a>].</p><p>Laboratory testing may include thyroid function tests, vitamin levels, and other testing (anti-gliadin, anti-GAD antibodies, HIV serology) in the appropriate clinical setting.</p><p>As with other paraneoplastic syndromes involving the nervous system, cerebrospinal fluid (CSF) examination can show inflammatory changes, at least in the early stages of the illness [<a href="#rid20">20</a>]. A mild pleocytosis (10 to 50 lymphocytes) and a mild elevation of protein are characteristic. Some patients with PCD or extensive encephalitis have the 14-3-3 protein characteristic of CJD in the CSF [<a href="#rid58">58</a>]. This might create some diagnostic confusion if a tumor is not evident because of symptom overlap between paraneoplastic disease and CJD. It is likely that the 14-3-3 protein in this setting reflects extensive central nervous system (CNS) damage rather than CJD. Immunoblotting reveals the 14-3-3 protein as a double band (similar to other false-positive results) rather than the single band in CJD. (See  <a class="medical medical_review" href="/d/html/5084.html" rel="external">"Creutzfeldt-Jakob disease"</a>.)</p><p>Paraneoplastic biomarkers should be sought in the patient's CSF and serum  (<a class="graphic graphic_table graphicRef135170" href="/d/graphic/135170.html" rel="external">table 1</a>). Not all biomarkers have commercially available testing, and some antigens remain to be characterized. Thus, negative results do not exclude a paraneoplastic or autoimmune disorder. A sample of a patient's CSF and serum should be sent to a research laboratory for examination in these cases. Other caveats regarding antibody screening are discussed separately. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Antibody screening'</a>.)</p><p>If the patient does not have a known cancer diagnosis, evaluation for occult malignancy should also ensue. The presence of paraneoplastic biomarkers may help direct further evaluation if initial screening is negative  (<a class="graphic graphic_table graphicRef135170" href="/d/graphic/135170.html" rel="external">table 1</a>). Tumors may be small; in some cases 18-F fluorodeoxyglucose PET (FDG-PET) or exploratory laparotomy were the only means of identifying the underlying lesion [<a href="#rid20">20,59</a>]. In a minority of patients with PCD, no tumor is identified despite vigorous investigations [<a href="#rid20">20,21,37</a>]. In such cases, serial investigations are advised. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Search for occult malignancy'</a>.)</p><p class="headingAnchor" id="H15807413"><span class="h1">TREATMENT AND PROGNOSIS</span><span class="headingEndMark"> — </span>Neurologic outcome for classic PCD is often poor; most patients (75 to 80 percent) become and remain nonambulatory [<a href="#rid37">37</a>]. Treatment of the underlying tumor is considered essential for neurologic stabilization; clinical improvement is less likely but can occur [<a href="#rid1">1,2,20,37</a>].</p><p>Immunotherapy is often used, but does not clearly affect neurologic outcome. In one larger case series, immunotherapy was not significantly associated with recovery [<a href="#rid37">37</a>]. However, there are anecdotal reports of neurologic improvement in patients tried on various immunologic therapies, including plasma exchange, intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), corticosteroids, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, given individually or in combination [<a href="#rid9">9,31,37,60-70</a>]. One literature review of 15 cases found that treatment with IVIG was more likely to be associated with a good outcome if it was administered within three months of symptom onset [<a href="#rid71">71</a>]. There are also rare reports of spontaneous improvement. In contrast to classic PCD, some patients with paraneoplastic cerebellar ataxia can have responses to immunotherapy and cancer treatment [<a href="#rid16">16,52</a>].</p><p>Given the overall poor prognosis of PCD with substantial neurologic disability, a trial of immunotherapy seems reasonable. As most antibodies are directed against intracellular proteins, which implies cytotoxic T cell mechanisms, it is reasonable to focus the treatment on (1) controlling the cancer, and (2) controlling the cytotoxic T cell response. Towards this goal, we favor the use of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> over plasma exchange or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>. (See  <a class="medical medical_review" href="/d/html/5188.html" rel="external">"Overview of paraneoplastic syndromes of the nervous system", section on 'Treatment and prognosis'</a>.)</p><p>The type of antibody appears to affect neurologic prognosis. Patients with PCD associated with anti-Hu or anti-Yo antibodies are less likely to recover, while those with anti-Tr, anti-Ri, anti-metabotropic glutamate receptor 1 (mGluR1), or anti-CRMP5 antibodies may have a somewhat better chance of neurologic improvement [<a href="#rid2">2,12,33,72</a>]. In some reports, younger age and less severe disability at diagnosis and intervention appear to favorably affect prognosis.</p><p>Survival also varies with the type of associated antibody as well as the underlying neoplasm. In one series, survival was worse in patients with anti-Hu antibodies (median 7 months) and those with anti-Yo antibodies (median 13 months) compared with patients who had anti-Tr or anti-Ri antibodies (median survival 113 and 69 months, respectively) [<a href="#rid37">37</a>]. In another series, median survival was 11 months in patients with anti-Hu antibodies compared with 48 months in those with anti-CV2 antibodies [<a href="#rid73">73</a>]. Advanced age has a negative impact on survival. While some reports find that neurologic morbidity contributes most substantively to mortality [<a href="#rid20">20,37</a>], others have found that cancer progression was more important [<a href="#rid21">21,60</a>].</p><p class="headingAnchor" id="H1101526344"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117968.html" rel="external">"Society guideline links: Paraneoplastic neurologic disorders"</a>.)</p><p class="headingAnchor" id="H15807562"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated cancers</strong> – Paraneoplastic cerebellar degeneration (PCD) is an uncommon disorder that can be associated with any cancer; the most commonly associated are lung cancer (particularly small cell lung cancer [SCLC]), gynecologic and breast cancer, and lymphoma (particularly Hodgkin disease [HD]). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated antibodies</strong> – A number of autoantibodies associated with PCD have been characterized. Individual autoantibodies are often linked to specific cancer types and/or clinical syndromes  (<a class="graphic graphic_table graphicRef135170" href="/d/graphic/135170.html" rel="external">table 1</a>). As an example, patients with PCD and anti-Yo antibodies typically have breast or gynecologic cancer and isolated cerebellar deficits and pathology. Other antibodies along with their associated tumors and characteristic clinical features are outlined. (See <a class="local">'Pathogenesis'</a> above and <a class="local">'Associated antibodies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with PCD typically present with dizziness, nausea, and vomiting, often beginning acutely and followed several days later by gait instability and other cerebellar signs. Many patients with PCD develop cerebellar dysfunction along with other paraneoplastic neurologic disorders such as Lambert-Eaton myasthenic syndrome (LEMS) and encephalomyelitis. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Neuroimaging and cerebrospinal fluid (CSF) analysis are important to exclude other conditions; findings in PCD may be normal or nonspecifically abnormal. Paraneoplastic biomarkers provide supporting evidence for the diagnosis. If the patient does not have a known cancer diagnosis, evaluation for occult malignancy should ensue. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – As most antibodies are directed against intracellular proteins, which implies cytotoxic T cell mechanisms, we favor the use of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> over plasma exchange or intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG). By contrast, paraneoplastic cerebellar ataxia in some patients can be treatment responsive. (See <a class="local">'Treatment and prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Depending on the type of underlying antibody and associated neoplasm, the neurologic symptoms of patients with PCD may stabilize or rarely improve with antitumor treatment and/or immunotherapy. (See <a class="local">'Treatment and prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7:327.</a></li><li><a class="nounderline abstract_t">Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120 ( Pt 8):1279.</a></li><li><a class="nounderline abstract_t">Fukuda T, Motomura M, Nakao Y, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003; 53:21.</a></li><li><a class="nounderline abstract_t">Furneaux HM, Rosenblum MK, Dalmau J, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322:1844.</a></li><li><a class="nounderline abstract_t">Rojas-Marcos I, Rousseau A, Keime-Guibert F, et al. Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) 2003; 82:216.</a></li><li><a class="nounderline abstract_t">Fathallah-Shaykh H, Wolf S, Wong E, et al. Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A 1991; 88:3451.</a></li><li><a class="nounderline abstract_t">Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4:1321.</a></li><li><a class="nounderline abstract_t">Graus F, Gultekin SH, Ferrer I, et al. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathol 1998; 96:1.</a></li><li><a class="nounderline abstract_t">Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60:230.</a></li><li><a class="nounderline abstract_t">Antoine JC, Honnorat J, Camdessanché JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 2001; 49:214.</a></li><li><a class="nounderline abstract_t">Honnorat J, Antoine JC, Derrington E, et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996; 61:270.</a></li><li><a class="nounderline abstract_t">de la Sayette V, Bertran F, Honnorat J, et al. Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 1998; 55:405.</a></li><li><a class="nounderline abstract_t">Bataller L, Wade DF, Graus F, et al. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004; 62:778.</a></li><li><a class="nounderline abstract_t">Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000; 47:297.</a></li><li><a class="nounderline abstract_t">Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001; 50:301.</a></li><li><a class="nounderline abstract_t">Sillevis Smitt P, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342:21.</a></li><li><a class="nounderline abstract_t">Bataller L, Sabater L, Saiz A, et al. Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration. Ann Neurol 2004; 56:575.</a></li><li><a class="nounderline abstract_t">Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47:9.</a></li><li><a class="nounderline abstract_t">Aye MM, Kasai T, Tashiro Y, et al. CD8 positive T-cell infiltration in the dentate nucleus of paraneoplastic cerebellar degeneration. J Neuroimmunol 2009; 208:136.</a></li><li><a class="nounderline abstract_t">Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42:1931.</a></li><li><a class="nounderline abstract_t">Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55:713.</a></li><li><a class="nounderline abstract_t">McKeon A, Tracy JA, Pittock SJ, et al. Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond. Arch Neurol 2011; 68:1282.</a></li><li><a class="nounderline abstract_t">Sutton IJ, Fursdon Davis CJ, Esiri MM, et al. Anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus. Ann Neurol 2001; 49:253.</a></li><li><a class="nounderline abstract_t">Meglic B, Graus F, Grad A. Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with gastric adenocarcinoma. J Neurol Sci 2001; 185:135.</a></li><li><a class="nounderline abstract_t">Krakauer J, Balmaceda C, Gluck JT, et al. Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin. Neurology 1996; 46:1486.</a></li><li><a class="nounderline abstract_t">Matschke J, Kromminga A, Erbersdobler A, et al. Paraneoplastic cerebellar degeneration and anti-Yo antibodies in a man with prostatic adenocarcinoma. J Neurol Neurosurg Psychiatry 2007; 78:775.</a></li><li><a class="nounderline abstract_t">Debes JD, Lagarde SM, Hulsenboom E, et al. Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of the gastroesophageal junction. Dig Surg 2007; 24:395.</a></li><li><a class="nounderline abstract_t">Totland C, Aarskog NK, Eichler TW, et al. CDR2 antigen and Yo antibodies. Cancer Immunol Immunother 2011; 60:283.</a></li><li><a class="nounderline abstract_t">Kråkenes T, Herdlevaer I, Raspotnig M, et al. CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration. Ann Neurol 2019; 86:316.</a></li><li><a class="nounderline abstract_t">Greene M, Lai Y, Baella N, et al. Antibodies to Delta/notch-like epidermal growth factor-related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma. JAMA Neurol 2014; 71:1003.</a></li><li><a class="nounderline abstract_t">Hammack J, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology 1992; 42:1938.</a></li><li><a class="nounderline abstract_t">Geromin A, Candoni A, Marcon G, et al. Paraneoplastic cerebellar degeneration associated with anti-neuronal anti-Tr antibodies in a patient with Hodgkin's disease. Leuk Lymphoma 2006; 47:1960.</a></li><li><a class="nounderline abstract_t">Briani C, Vitaliani R, Grisold W, et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology 2011; 76:705.</a></li><li><a class="nounderline abstract_t">de Graaff E, Maat P, Hulsenboom E, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012; 71:815.</a></li><li><a class="nounderline abstract_t">Marignier R, Chenevier F, Rogemond V, et al. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol 2010; 67:627.</a></li><li><a class="nounderline abstract_t">Lopez-Chiriboga AS, Komorowski L, Kümpfel T, et al. Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes. Neurology 2016; 86:1009.</a></li><li><a class="nounderline abstract_t">Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126:1409.</a></li><li><a class="nounderline abstract_t">Clouston PD, Saper CB, Arbizu T, et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology 1992; 42:1944.</a></li><li><a class="nounderline abstract_t">Graus F, Lang B, Pozo-Rosich P, et al. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002; 59:764.</a></li><li><a class="nounderline abstract_t">Brieva-Ruíz L, Diaz-Hurtado M, Matias-Guiu X, et al. Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study. Clin Neurol Neurosurg 2008; 110:1044.</a></li><li><a class="nounderline abstract_t">de Andrés C, Esquivel A, de Villoria JG, et al. Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study. J Neurol Neurosurg Psychiatry 2006; 77:562.</a></li><li><a class="nounderline abstract_t">Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146.</a></li><li><a class="nounderline abstract_t">Dalmau J, Gultekin SH, Voltz R, et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122 ( Pt 1):27.</a></li><li><a class="nounderline abstract_t">Rosenfeld MR, Eichen JG, Wade DF, et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50:339.</a></li><li><a class="nounderline abstract_t">Mandel-Brehm C, Dubey D, Kryzer TJ, et al. Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. N Engl J Med 2019; 381:47.</a></li><li><a class="nounderline abstract_t">Maudes E, Landa J, Muñoz-Lopetegi A, et al. Clinical significance of Kelch-like protein 11 antibodies. Neurol Neuroimmunol Neuroinflamm 2020; 7.</a></li><li><a class="nounderline abstract_t">Sabater L, Bataller L, Suárez-Calvet M, et al. ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J Neuroimmunol 2008; 201-202:163.</a></li><li><a class="nounderline abstract_t">Höftberger R, Kovacs GG, Sabater L, et al. Protein kinase Cγ antibodies and paraneoplastic cerebellar degeneration. J Neuroimmunol 2013; 256:91.</a></li><li><a class="nounderline abstract_t">Sabater L, Bataller L, Carpentier AF, et al. Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer. J Neurol Neurosurg Psychiatry 2006; 77:1359.</a></li><li><a class="nounderline abstract_t">Höftberger R, Sabater L, Velasco F, et al. Carbonic anhydrase-related protein VIII antibodies and paraneoplastic cerebellar degeneration. Neuropathol Appl Neurobiol 2014; 40:650.</a></li><li><a class="nounderline abstract_t">Berzero G, Hacohen Y, Komorowski L, et al. Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies. Neurol Neuroimmunol Neuroinflamm 2017; 4:e326.</a></li><li><a class="nounderline abstract_t">Do LD, Gupton SL, Tanji K, et al. TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration. Cerebellum 2019; 18:245.</a></li><li><a class="nounderline abstract_t">Ruiz-García R, Martínez-Hernández E, Joubert B, et al. Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Neurol Neuroimmunol Neuroinflamm 2020; 7.</a></li><li class="breakAll">Cancer and the Nervous System, Henson RA, Urich H (Eds), Blackwell Scientific, Oxford 1982. p.314.</li><li><a class="nounderline abstract_t">Dalmau J, Gonzalez RG, Lerwill MF. Case records of the Massachusetts General Hospital. Case 4-2007. A 56-year-old woman with rapidly progressive vertigo and ataxia. N Engl J Med 2007; 356:612.</a></li><li><a class="nounderline abstract_t">Choi KD, Kim JS, Park SH, et al. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 2006; 77:525.</a></li><li><a class="nounderline abstract_t">Scheid R, Voltz R, Briest S, et al. Clinical insights into paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 2006; 77:529.</a></li><li><a class="nounderline abstract_t">Saiz A, Graus F, Dalmau J, et al. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol 1999; 46:774.</a></li><li><a class="nounderline abstract_t">Marchand V, Graveleau J, Lanctin-Garcia C, et al. A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET. Gynecol Oncol 2007; 105:545.</a></li><li><a class="nounderline abstract_t">Cao Y, Abbas J, Wu X, et al. Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature. Gynecol Oncol 1999; 75:178.</a></li><li><a class="nounderline abstract_t">Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68:479.</a></li><li><a class="nounderline abstract_t">Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253:16.</a></li><li><a class="nounderline abstract_t">Esposito M, Penza P, Orefice G, et al. Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. J Neurooncol 2008; 86:363.</a></li><li><a class="nounderline abstract_t">David YB, Warner E, Levitan M, et al. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer 1996; 78:2153.</a></li><li><a class="nounderline abstract_t">Blaes F, Strittmatter M, Merkelbach S, et al. Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol 1999; 246:299.</a></li><li><a class="nounderline abstract_t">Taniguchi Y, Tanji C, Kawai T, et al. A case report of plasmapheresis in paraneoplastic cerebellar ataxia associated with anti-Tr antibody. Ther Apher Dial 2006; 10:90.</a></li><li><a class="nounderline abstract_t">Mowzoon N, Bradley WG. Successful immunosuppressant therapy of severe progressive cerebellar degeneration and sensory neuropathy: a case report. J Neurol Sci 2000; 178:63.</a></li><li><a class="nounderline abstract_t">Counsell CE, McLeod M, Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology 1994; 44:1184.</a></li><li><a class="nounderline abstract_t">Thöne J, Hohaus A, Lamprecht S, et al. Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration. J Neurol Sci 2008; 272:171.</a></li><li><a class="nounderline abstract_t">Phuphanich S, Brock C. Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J Neurooncol 2007; 81:67.</a></li><li><a class="nounderline abstract_t">Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. J Neurooncol 2003; 63:187.</a></li><li><a class="nounderline abstract_t">Graus F, Dalmau J, Valldeoriola F, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997; 74:55.</a></li><li><a class="nounderline abstract_t">Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009; 80:412.</a></li></ol></div><div id="topicVersionRevision">Topic 15822 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18339348" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Paraneoplastic syndromes of the CNS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9278623" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509844" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2348838" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12792307" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2014264" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9809559" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tumor-specific killer cells in paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9678507" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12552036" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11220741" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8795598" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9520015" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15007130" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716248" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11558786" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620645" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15389893" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632096" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217169" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : CD8 positive T-cell infiltration in the dentate nucleus of paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1407575" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10980743" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670387" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Purkinje cell cytoplasmic autoantibody type 1 accompaniments: the cerebellum and beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11220746" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11311295" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with gastric adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628511" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17189300" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Paraneoplastic cerebellar degeneration and anti-Yo antibodies in a man with prostatic adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785986" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of the gastroesophageal junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21080165" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : CDR2 antigen and Yo antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31148214" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24935874" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Antibodies to Delta/notch-like epidermal growth factor-related receptor in patients with anti-Tr, paraneoplastic cerebellar degeneration, and Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1407576" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065013" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Paraneoplastic cerebellar degeneration associated with anti-neuronal anti-Tr antibodies in a patient with Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339498" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Spectrum of paraneoplastic disease associated with lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22447725" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20457964" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888994" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12764061" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1407577" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12221175" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18701208" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Anti-Ri-associated paraneoplastic cerebellar degeneration and breast cancer: an autopsy case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543544" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11220734" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10050892" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11558790" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Molecular and clinical diversity in paraneoplastic immunity to Ma proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31269365" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31953318" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical significance of Kelch-like protein 11 antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18639938" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23273977" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Protein kinase Cγantibodies and paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16801349" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24446689" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Carbonic anhydrase-related protein VIII antibodies and paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28203616" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Paraneoplastic cerebellar degeneration associated with anti-ITPR1 antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30350014" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31826987" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31826987" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287482" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Case records of the Massachusetts General Hospital. Case 4-2007. A 56-year-old woman with rapidly progressive vertigo and ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543536" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543537" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical insights into paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10553996" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17368524" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10502450" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10727484" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16444604" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17924058" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Successful treatment of paraneoplastic cerebellar degeneration with Rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918408" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10367699" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16556143" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A case report of plasmapheresis in paraneoplastic cerebellar ataxia associated with anti-Tr antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11018251" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Successful immunosuppressant therapy of severe progressive cerebellar degeneration and sensory neuropathy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8208425" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18632117" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16773214" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12825823" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9119979" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18931014" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
